Promacta Kit is owned by Novartis.
Promacta Kit contains Eltrombopag Olamine.
Promacta Kit has a total of 6 drug patents out of which 1 drug patent has expired.
Expired drug patents of Promacta Kit are:
Promacta Kit was authorised for market use on 24 August, 2015.
Promacta Kit is available in for suspension;oral dosage forms.
Promacta Kit can be used as treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy; treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (itp), treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (itp); treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy, patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy; treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (itp); combination with immunosuppressive therapy for first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia; treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy.
The generics of Promacta Kit are possible to be released after 13 January, 2026.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7160870 | NOVARTIS | Thrombopoietin mimetics |
Nov, 2022
(2 months ago) | |
US7547719 | NOVARTIS | 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) |
Jul, 2025
(2 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7160870
(Pediatric) | NOVARTIS | Thrombopoietin mimetics |
May, 2023
(3 months from now) | |
US7795293 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
May, 2023
(3 months from now) | |
US7795293
(Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Nov, 2023
(9 months from now) | |
US7547719
(Pediatric) | NOVARTIS | 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) |
Jan, 2026
(2 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Nov 16, 2025 |
Pediatric Exclusivity (PED) | Feb 26, 2022 |
Drugs and Companies using ELTROMBOPAG OLAMINE ingredient
Market Authorisation Date: 24 August, 2015
Treatment: Treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (itp); Treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy; Patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy; Combination with immunosuppressive therapy for first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia
Dosage: FOR SUSPENSION;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic